NASDAQ:NXGL NEXGEL (NXGL) Stock Price, News & Analysis $2.97 -0.06 (-1.98%) Closing price 04:00 PM EasternExtended Trading$3.00 +0.03 (+1.01%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NEXGEL Stock (NASDAQ:NXGL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NEXGEL alerts:Sign Up Key Stats Today's Range$2.91▼$3.1950-Day Range$2.66▼$3.8252-Week Range$1.84▼$5.10Volume67,375 shsAverage Volume64,704 shsMarket Capitalization$20.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.Read More… Remove Ads NEXGEL Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreNXGL MarketRank™: NEXGEL scored higher than 22% of companies evaluated by MarketBeat, and ranked 849th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for NEXGEL. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NEXGEL is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NEXGEL is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNEXGEL has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NEXGEL's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.99% of the float of NEXGEL has been sold short.Short Interest Ratio / Days to CoverNEXGEL has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NEXGEL has recently decreased by 2.73%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNEXGEL does not currently pay a dividend.Dividend GrowthNEXGEL does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.99% of the float of NEXGEL has been sold short.Short Interest Ratio / Days to CoverNEXGEL has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NEXGEL has recently decreased by 2.73%, indicating that investor sentiment is improving. News and Social Media2.8 / 5News Sentiment0.95 News SentimentNEXGEL has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for NEXGEL this week, compared to 1 article on an average week.Search Interest4 people have searched for NXGL on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NEXGEL insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,730.00 in company stock.Percentage Held by Insiders24.86% of the stock of NEXGEL is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.21% of the stock of NEXGEL is held by institutions.Read more about NEXGEL's insider trading history. Receive NXGL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NEXGEL and its competitors with MarketBeat's FREE daily newsletter. Email Address NXGL Stock News HeadlinesAdam R. Levy Sells 4,000 Shares of NEXGEL, Inc. (NASDAQ:NXGL) StockMarch 6, 2025 | insidertrades.comNEXGEL, Inc. (NASDAQ:NXGL) Q4 2024 Earnings Call TranscriptMarch 26 at 8:33 AM | insidermonkey.comTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’s secret plan to trigger the greatest transfer of wealth since FDR and LBJ – trillions of dollars could be redistributed.March 26, 2025 | Porter & Company (Ad)Earnings call transcript: Nexgel Q4 2024 sees revenue surge, stock jumpsMarch 26 at 6:11 AM | investing.comNEXGEL, Inc. Reports Record Q4 and Full Year 2024 Revenue Growth of 181% and 112% Respectively, Forecasts $13 Million in Revenue for 2025March 26 at 6:11 AM | nasdaq.comNEXGEL Reports Record Revenue Growth in 2024March 25 at 12:24 AM | tipranks.comNEXGEL targets $13M revenue in 2025 amid product and partnership expansionMarch 24 at 10:58 PM | msn.comNEXGEL, Inc. (NXGL) Q4 2024 Earnings Call TranscriptMarch 24 at 6:01 PM | seekingalpha.comSee More Headlines NXGL Stock Analysis - Frequently Asked Questions How have NXGL shares performed this year? NEXGEL's stock was trading at $4.46 at the beginning of the year. Since then, NXGL shares have decreased by 33.4% and is now trading at $2.97. View the best growth stocks for 2025 here. How were NEXGEL's earnings last quarter? NEXGEL, Inc. (NASDAQ:NXGL) issued its earnings results on Monday, March, 24th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02. The firm earned $3.04 million during the quarter, compared to analyst estimates of $2.99 million. NEXGEL had a negative net margin of 52.60% and a negative trailing twelve-month return on equity of 71.19%. When did NEXGEL IPO? NEXGEL (NXGL) raised $14 million in an initial public offering (IPO) on Wednesday, December 22nd 2021. The company issued 2,100,000 shares at a price of $6.83 per share. Maxim Group LLC acted as the underwriter for the IPO. Who are NEXGEL's major shareholders? Top institutional investors of NEXGEL include Renaissance Technologies LLC (2.33%), Geode Capital Management LLC (0.89%), Two Sigma Securities LLC (0.18%) and IFP Advisors Inc (0.16%). Insiders that own company stock include John Nachum Stein, Nachum Stein, Adam R Levy, Steven Mark Glassman, Scott Robert Henry, Adam E Drapczuk III and David Stefansky. View institutional ownership trends. How do I buy shares of NEXGEL? Shares of NXGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NEXGEL own? Based on aggregate information from My MarketBeat watchlists, some other companies that NEXGEL investors own include Lexicon Pharmaceuticals (LXRX), Aditxt (ADTX), Helius Medical Technologies (HSDT), Onconova Therapeutics (ONTX), EchoStar (SATS), American Battery Technology (ABML) and Aumann (AAG). Company Calendar Last Earnings3/24/2025Today3/26/2025Next Earnings (Estimated)4/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:NXGL CIK1468929 Webnexgel.com Phone215-702-8550FaxN/AEmployees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,160,000.00 Net Margins-52.60% Pretax Margin-56.85% Return on Equity-71.19% Return on Assets-34.79% Debt Debt-to-Equity Ratio0.19 Current Ratio1.51 Quick Ratio0.93 Sales & Book Value Annual Sales$6.73 million Price / Sales3.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.90 per share Price / Book3.37Miscellaneous Outstanding Shares6,791,000Free Float5,103,000Market Cap$20.58 million OptionableNot Optionable Beta0.62 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:NXGL) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NEXGEL, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NEXGEL With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.